CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH) Sep 8, 2021
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity Aug 10, 2021
CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021 Aug 4, 2021
CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity Jul 14, 2021
